1-[1-(1,1-dimethylethyl)-4-piperidinyl]piperazine | 775287-90-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 1-[1-(1,1-dimethylethyl)-4-piperidinyl]piperazine
• 英文别名: 1-(1-Tert-butylpiperidin-4-yl)piperazine
• CAS: 775287-90-6
• 化学式: C₁₃H₂₇N₃
• 分子量: 225.377
• InChiKey: DLFBTVIZFGUKEB-UHFFFAOYSA-N

物化性质

• 沸点：
  306.0±10.0 °C(Predicted)
• 密度：
  0.975±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  18.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  4-[1-(1,1-dimethylethyl)-4-piperidinyl]-1-piperazinecarboxylic acid,phenylmethyl ester 在 palladium 10% on activated carbon 氢气 作用下， 以 甲醇 为溶剂， 反应 2.0h， 以75%的产率得到1-[1-(1,1-dimethylethyl)-4-piperidinyl]piperazine
  参考文献：
  名称：

  Benzenesulphonamide derivatives, method for production and use thereof for treatment of pain

  摘要：

  本发明涉及新型苯磺酰胺化合物，由公式I和描述所定义，其制备方法及在治疗中的用途。

  公开号：

  US20060178360A1

文献信息

• PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS
  申请人：ARIAD Pharmaceuticals, Inc.

  公开号：US20170218000A1

  公开（公告）日：2017-08-03

  The invention features compounds of the general formula (I) in which the variable groups are as defined herein, and to their preparation and use.

  本发明涉及通式（I）中的化合物，其中变量基团如本文所定义，以及其制备和使用。
• Pyrimidine derivative and use thereof
  申请人：Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.

  公开号：US10695347B2

  公开（公告）日：2020-06-30

  The present invention provides a pyrimidine derivative and a use thereof. The pyrimidine derivative is the compound shown in formula I or a pharmaceutically acceptable salt, hydrate, solvate, metabolite or prodrug thereof, wherein, R1, R2, R3, R4 and R5 are, for example, as defined in the specification. The compound can act as an ALK inhibitor, and is for preparing an anti-tumor medicament for suppressing an anaplastic lymphoma kinase.

  本发明提供了一种嘧啶衍生物及其用途。嘧啶衍生物是式 I 所示的化合物或其药学上可接受的盐、水合物、溶液、代谢物或原药，其中，R1、R2、R3、R4 和 R5 例如如说明书中所定义。该化合物可作为 ALK 抑制剂，用于制备抑制无性淋巴瘤激酶的抗肿瘤药物。
• DERIVES DU BENZENESULFONAMIDE, LEUR PROCEDE DE PREPARATION ET LEUR UTILISATION POUR LE TRAITEMENT DE LA DOULEUR
  申请人：LABORATOIRES FOURNIER S.A.

  公开号：EP1606288A1

  公开（公告）日：2005-12-21
• Methods for Inhibiting Cell Proliferation in EGFR-Driven Cancers
  申请人：Dalgarno David C.

  公开号：US20140024620A1

  公开（公告）日：2014-01-23

  The invention features a method for treating patients who have an EGFR-driven cancer, which is, or has become, refractory to a tyrosine kinase inhibitor, such as eriotinib and gefitinib, by administering a compound of formula (I) to the patient. The invention also features treating EGFR-driven cancers having an EGFR mutation identified herein.
• HETEROCYCLIC COMPOUNDS
  申请人：KYORIN PHARMACEUTICAL CO., LTD.

  公开号：US20170008888A1

  公开（公告）日：2017-01-12

  Provided herein are compounds of formula I and compositions containing the compounds. The compounds and compositions are useful in the methods of inhibiting the action of ERK5, a BET family protein or both. In certain embodiments, the compounds and compositions are useful in the prevention, amelioration or treatment of a ERK5-mediated disease, a BET protein-mediated disease or both.